Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827105 | 1.00 | HSD11B1 (1.00) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| Water SCHEMBL1003615 | 0.99 | HSD11B1 (0.98) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| Water SCHEMBL1003616 | 0.99 | HSD11B1 (0.98) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| SCHEMBL31419779 | 0.92 | HSD11B1 (0.84) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| SCHEMBL16868571 | 0.91 | HSD11B1 (0.83) | HSD11B1CYP3A4CYP2D6CYP2C9NR1I2 | |
| SCHEMBL2667918 | 0.88 | HSD11B1 (0.78) | HSD11B1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2667625 | 0.88 | HSD11B1 (0.78) | HSD11B1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2667471 | 0.87 | HSD11B1 (0.79) | HSD11B1NR1I2CYP2C19HSD11B2 | |
| SCHEMBL14619946 | 0.85 | HSD11B1 (0.74) | HSD11B1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4538415 | 0.85 | HSD11B1 (0.75) | HSD11B1NR1I2CYP2C19HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875642-B2 | 3-[1-(4-Chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole anhydrate; Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | claimed |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | MERCK SHARP & DOHME LLC | 2009-07-23 | — | — | US | claimed |
| EP-1711477-A4 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | claimed |
| JP-2007519726-A | — | — | 2007-07-19 | — | — | JP | claimed |
| EP-1711477-A1 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Merck & Co., Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| WO-2005073200-A1 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | claimed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | disclosed |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | disclosed |
| US-10668074-B2 | — | — | 2020-06-02 | — | — | US | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-1910161-A | Novel crystal form of 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor | MERCK & CO INC (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1711477-A1 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Merck & Co., Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005073200-A1 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK SHARP & DOHME LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885CYP3A4 269/4885CYP2D6 325/4885 |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885CYP3A4 133/4885CYP2D6 193/4885 |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | HSD11B1 780/4885CYP3A4 175/4885CYP2D6 246/4885 |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP3A4 323/4885CYP2D6 277/4885 |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | HSD11B1 780/4885CYP3A4 175/4885CYP2D6 246/4885 |
| US-20090186928-A1 | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885CYP3A4 86/4885CYP2D6 311/4885 |
| US-10668074-B2 | — | DPP4, DPP7, DPP3 | HSD11B1 887/4885CYP3A4 135/4885CYP2D6 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.